Table of Contents
ISRN Inflammation
Volume 2013 (2013), Article ID 512103, 23 pages
http://dx.doi.org/10.1155/2013/512103
Review Article

The Enigmatic Cytokine Oncostatin M and Roles in Disease

McMaster Immunology Research Centre, Department of Pathology and Molecular Medicine, McMaster University, 1280 Main Street, West, Hamilton, ON, Canada L8S 4K1

Received 3 September 2013; Accepted 29 September 2013

Academic Editors: R. Gong and N. Horwood

Copyright © 2013 Carl D. Richards. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Tanaka and A. Miyajima, “Oncostatin M, a multifunctional cytokine,” Reviews of Physiology, Biochemistry and Pharmacology, vol. 149, pp. 39–52, 2003. View at Google Scholar · View at Scopus
  2. S.-H. Chen and E. N. Benveniste, “Oncostatin M: a pleiotropic cytokine in the central nervous system,” Cytokine and Growth Factor Reviews, vol. 15, no. 5, pp. 379–391, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. J. S. Silver and C. A. Hunter, “gp130 at the nexus of inflammation, autoimmunity, and cancer,” Journal of Leukocyte Biology, vol. 88, no. 6, pp. 1145–1156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. N. A. Sims and N. C. Walsh, “GP130 cytokines and bone remodelling in health and disease,” BMB Reports, vol. 43, no. 8, pp. 513–523, 2010. View at Google Scholar · View at Scopus
  5. J. M. Zarling, M. Shoyab, and H. Marquardt, “Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 24, pp. 9739–9743, 1986. View at Google Scholar · View at Scopus
  6. N. Malik, J. C. Kallestad, N. L. Gunderson et al., “Molecular cloning, sequence analysis, and functional expression of a novel growth regulator, oncostatin M,” Molecular and Cellular Biology, vol. 9, no. 7, pp. 2847–2853, 1989. View at Google Scholar · View at Scopus
  7. P. S. Linsley, J. Kallestad, V. Ochs, and M. Neubauer, “Cleavage of a hydrophilic C-terminal domain increases growth-inhibitory activity of oncostatin M,” Molecular and Cellular Biology, vol. 10, no. 5, pp. 1882–1890, 1990. View at Google Scholar · View at Scopus
  8. A. Yoshimura, M. Ichihara, I. Kinjyo et al., “Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway,” EMBO Journal, vol. 15, no. 5, pp. 1055–1063, 1996. View at Google Scholar · View at Scopus
  9. A. Okaya, J. Kitanaka, N. Kitanaka et al., “Oncostatin M inhibits proliferation of rat oval cells, OC15-5, inducing differentiation into hepatocytes,” American Journal of Pathology, vol. 166, no. 3, pp. 709–719, 2005. View at Google Scholar · View at Scopus
  10. J. Bravo and J. K. Heath, “Receptor recognition by gp130 cytokines,” The EMBO Journal, vol. 19, pp. 2399–2411, 2000. View at Publisher · View at Google Scholar
  11. M. C. Deller, K. R. Hudson, S. Ikemizu, J. Bravo, E. Y. Jones, and J. K. Heath, “Crystal structure and functional dissection of the cytostatic cytokine oncostatin M,” Structure, vol. 8, no. 8, pp. 863–874, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Plun-Favreau, D. Perret, C. Diveu et al., “Leukemia inhibitory factor (LIF), cardiotrophin-1, and oncostatin M share structural binding determinants in the immunoglobulin-like domain of LIF receptor,” The Journal of Biological Chemistry, vol. 278, no. 29, pp. 27169–27179, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Somasundaram, M. Ruehl, B. Schaefer et al., “Interstitial collagens I, III, and VI sequester and modulate the multifunctional cytokine oncostatin M,” The Journal of Biological Chemistry, vol. 277, no. 5, pp. 3242–3246, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Suda, K. Chida, A. Todate et al., “Oncostatin M production by human dendritic cells in response to bacterial products,” Cytokine, vol. 17, no. 6, pp. 335–340, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Grenier, M. Dehoux, A. Boutten et al., “Oncostatin M production and regulation by human polymorphonuclear neutrophils,” Blood, vol. 93, no. 4, pp. 1413–1421, 1999. View at Google Scholar · View at Scopus
  16. A. Grenier, D. Combaux, J. Chastre et al., “Oncostatin M production by blood and alveolar neutrophils during acute lung injury,” Laboratory Investigation, vol. 81, no. 2, pp. 133–141, 2001. View at Google Scholar · View at Scopus
  17. C. Guillet, M. Fourcin, S. Chevalier, A. Pouplard, and H. Gascan, “ELISA detection of circulating levels of LIF, OSM, and CNTF in septic shock,” Annals of the New York Academy of Sciences, vol. 762, pp. 407–409, 1995. View at Google Scholar · View at Scopus
  18. S. M. Hurst, R. M. McLoughlin, J. Monslow et al., “Secretion of oncostatin M by infiltrating neutrophils: regulation of IL-6 and chemokine expression in human mesothelial cells,” Journal of Immunology, vol. 169, no. 9, pp. 5244–5251, 2002. View at Google Scholar · View at Scopus
  19. K. Ganesh, A. Das, R. Dickerson et al., “Prostaglandin E2 induces oncostatin M expression in human chronic wound macrophages through Axl receptor tyrosine kinase pathway,” The Journal of Immunology, vol. 189, pp. 2563–2573, 2012. View at Publisher · View at Google Scholar
  20. S. Tamura, Y. Morikawa, A. Miyajima, and E. Senba, “Expression of oncostatin M in hematopoietic organs,” Developmental Dynamics, vol. 225, no. 3, pp. 327–331, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Salamon, N. G. Shoham, I. Puxeddu, Y. Paitan, F. Levi-Schaffer, and Y. A. Mekori, “Human mast cells release oncostatin M on contact with activated T cells: possible biologic relevance,” Journal of Allergy and Clinical Immunology, vol. 121, no. 2, pp. 448–e5, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. D. J. Hilton, “LIF: lots of interesting functions,” Trends in Biochemical Sciences, vol. 17, no. 2, pp. 72–76, 1992. View at Google Scholar · View at Scopus
  23. T. Kishimoto, S. Akira, M. Narazaki, and T. Taga, “Interleukin-6 family of cytokines and gp130,” Blood, vol. 86, no. 4, pp. 1243–1254, 1995. View at Google Scholar · View at Scopus
  24. D. Kamimura, K. Ishihara, and T. Hirano, “IL-6 signal transduction and its physiological roles: the signal orchestration model,” Reviews of physiology, biochemistry and pharmacology, vol. 149, pp. 1–38, 2003. View at Google Scholar · View at Scopus
  25. M. Murakami, D. Kamimura, and T. Hirano, “New IL-6 (gp130) family cytokine members, CLC/NNT1/BSF3 and IL-27,” Growth Factors, vol. 22, no. 2, pp. 75–77, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. A. V. Villarino, E. Huang, and C. A. Hunter, “Understanding the pro- and anti-inflammatory properties of IL-27,” The Journal of Immunology, vol. 173, no. 2, pp. 715–720, 2004. View at Google Scholar · View at Scopus
  27. G. Senaldi, B. C. Varnum, C. S. Ulla Sarmiento et al., “Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 20, pp. 11458–11463, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Artis, A. Villarino, M. Silverman et al., “The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity,” The Journal of Immunology, vol. 173, no. 9, pp. 5626–5634, 2004. View at Google Scholar · View at Scopus
  29. T. Taga, “The signal transducer gp130 is shared by interleukin-6 family of haematopoietic and neurotrophic cytokines,” Annals of Medicine, vol. 29, no. 1, pp. 63–72, 1997. View at Google Scholar · View at Scopus
  30. P. C. Heinrich, I. Behrmann, G. Müller-Newen, F. Schaper, and L. Graeve, “Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway,” Biochemical Journal, vol. 334, no. 2, pp. 297–314, 1998. View at Google Scholar · View at Scopus
  31. I. Behrmann, H. M. Hermanns, C. Haan et al., “Signalling of interleukin-6 type cytokines via gp130, leukemia inhibitory factor (LIF) receptor and oncostatin M receptor,” European Cytokine Network, vol. 11, no. 3, pp. 491–492, 2000. View at Google Scholar · View at Scopus
  32. S. R. Dillon, C. Sprecher, A. Hammond et al., “Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice,” Nature Immunology, vol. 5, pp. 752–760, 2004. View at Google Scholar
  33. T. Taga, “gp130 and the interleukin-6 family of cytokines,” Annual Review of Immunology, vol. 15, pp. 797–819, 1997. View at Publisher · View at Google Scholar · View at Scopus
  34. P. C. Heinrich, I. Behrmann, S. Haan, H. M. Hermanns, G. Müller-Newen, and F. Schaper, “Principles of interleukin (IL)-6-type cytokine signalling and its regulation,” Biochemical Journal, vol. 374, no. 1, pp. 1–20, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Chevalier, M. Fourcin, O. Robledo, J. Wijdenes, A. Pouplard-Barthelaix, and H. Gascan, “Interleukin-6 family of cytokines induced activation of different functional sites expressed by gp130 transducing protein,” The Journal of Biological Chemistry, vol. 271, no. 25, pp. 14764–14772, 1996. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Liu, B. Modrell, A. Aruffo, S. Scharnowske, and M. Shoyab, “Interactions between oncostatin M and the IL-6 signal transducer, gp130,” Cytokine, vol. 6, no. 3, pp. 272–278, 1994. View at Publisher · View at Google Scholar · View at Scopus
  37. D. P. Gearing, M. R. Comeau, D. J. Friend et al., “The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor,” Science, vol. 255, no. 5050, pp. 1434–1437, 1992. View at Google Scholar · View at Scopus
  38. B. Mosley, C. De Imus, D. Friend et al., “Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation,” The Journal of Biological Chemistry, vol. 271, no. 51, pp. 32635–32643, 1996. View at Publisher · View at Google Scholar · View at Scopus
  39. D. K. Fritz, “The role of the oncostatin M—STAT6 axis in pulmonary eosinophilia, goblet cell hyperplasia, airway hyperresponsiveness and pulmonary fibrosis,” ETD Collection For McMaster University Paper AAINR64688, 2010. View at Google Scholar
  40. M. Ichihara, T. Hara, H. Kim, T. Murate, and A. Miyajima, “Oncostatin M and leukemia inhibitory factor do not use the same functional receptor in mice,” Blood, vol. 90, no. 1, pp. 165–173, 1997. View at Google Scholar · View at Scopus
  41. R. A. Lindberg, T. S.-C. Juan, A. A. Welcher et al., “Cloning and characterization of a specific receptor for mouse oncostatin M,” Molecular and Cellular Biology, vol. 18, no. 6, pp. 3357–3367, 1998. View at Google Scholar · View at Scopus
  42. M. Tanaka, T. Hara, N. G. Copeland, D. J. Gilbert, N. A. Jenkins, and A. Miyajima, “Reconstitution of the functional mouse oncostatin M (OSM) receptor: molecular cloning of the mouse OSM receptor β subunit,” Blood, vol. 93, no. 3, pp. 804–815, 1999. View at Google Scholar · View at Scopus
  43. J. Drechsler, J. Grotzinger, and H. M. Hermanns, “Characterization of the rat oncostatin M receptor complex which resembles the human, but differs from the murine cytokine receptor,” PLoS ONE, vol. 7, no. 8, 2012. View at Publisher · View at Google Scholar
  44. R. Soldi, A. Graziani, R. Benelli et al., “Oncostatin M activates phosphatidylinositol-3-kinase in Kaposi's sarcoma cells,” Oncogene, vol. 9, no. 8, pp. 2253–2260, 1994. View at Google Scholar · View at Scopus
  45. M. Faris, B. Ensoli, N. Stahl et al., “Differential activation of the extracellular signal-regulated kinase, Jun Kinase and Janus Kinase-Stat pathways by oncostatin M and basic fibroblast growth factor in AIDS-derived Kaposi's sarcoma cells,” AIDS, vol. 10, no. 4, pp. 369–378, 1996. View at Google Scholar · View at Scopus
  46. M. Ernst, A. Oates, and A. R. Dunn, “gp130-mediated signal transduction in embryonic stem cells involves activation of Jak and ras/mitogen-activated protein kinase pathways,” The Journal of Biological Chemistry, vol. 271, no. 47, pp. 30136–30143, 1996. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Symes, T. Gearan, J. Eby, and J. S. Fink, “Integration of Jak-Stat and AP-1 signaling pathways at the vasoactive intestinal peptide cytokine response element regulates ciliary neurotrophic factor-dependent transcription,” The Journal of Biological Chemistry, vol. 272, no. 15, pp. 9648–9654, 1997. View at Publisher · View at Google Scholar · View at Scopus
  48. L. F. Stancato, M. Sakatsume, M. David et al., “Beta interferon and oncostatin M activate Raf-1 and mitogen-activated protein kinase through a JAK1-dependent pathway,” Molecular and Cellular Biology, vol. 17, no. 7, pp. 3833–3840, 1997. View at Google Scholar · View at Scopus
  49. E. Pfitzner, S. Kliem, D. Baus, and C. M. Litterst, “The role of STATs in inflammation and inflammatory diseases,” Current Pharmaceutical Design, vol. 10, no. 23, pp. 2839–2850, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. C. M. Horvath, “STAT proteins and transcriptional responses to extracellular signals,” Trends in Biochemical Sciences, vol. 25, no. 10, pp. 496–502, 2000. View at Publisher · View at Google Scholar · View at Scopus
  51. K. Takeda and S. Akira, “STAT family of transcription factors in cytokine-mediated biological responses,” Cytokine and Growth Factor Reviews, vol. 11, no. 3, pp. 199–207, 2000. View at Publisher · View at Google Scholar · View at Scopus
  52. L. Hendry and S. John, “Regulation of STAT signalling by proteolytic processing,” European Journal of Biochemistry, vol. 271, no. 23-24, pp. 4613–4620, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. X. P. Chen, J. A. Losman, and P. Rothman, “SOCS proteins, regulators of intracellular signaling,” Immunity, vol. 13, no. 3, pp. 287–290, 2000. View at Google Scholar · View at Scopus
  54. B. Liu, J. Liao, X. Rao et al., “Inhibition of Stat1-mediated gene activation by PIAS1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 18, pp. 10626–10631, 1998. View at Publisher · View at Google Scholar · View at Scopus
  55. D. Tang, H. Okada, J. Ruland et al., “Akt is activated in response to an apoptotic signal,” The Journal of Biological Chemistry, vol. 276, no. 32, pp. 30461–30466, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. S. G. Kennedy, A. J. Wagner, S. D. Conzen et al., “The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal,” Genes and Development, vol. 11, no. 6, pp. 701–713, 1997. View at Google Scholar · View at Scopus
  57. H. G. Zhang, Y. Wang, J. F. Xie et al., “Regulation of tumor necrosis factor alpha-mediated apoptosis of rheumatoid arthritis synovial fibroblasts by the protein kinase Akt,” Arthritis & Rheumatism, vol. 44, pp. 1555–1567, 2001. View at Google Scholar
  58. L. Chang and M. Karin, “Mammalian MAP kinase signalling cascades,” Nature, vol. 410, no. 6824, pp. 37–40, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. P. Auguste, C. Guillet, M. Fourcin et al., “Signaling of type II oncostatin M receptor,” The Journal of Biological Chemistry, vol. 272, no. 25, pp. 15760–15764, 1997. View at Publisher · View at Google Scholar · View at Scopus
  60. H. M. Hermanns, S. Radtke, F. Schaper, P. C. Heinrich, and I. Behrmann, “Non-redundant signal transduction of interleukin-6-type cytokines: the adapter protein Shc is specifically recruited to the oncostatin M receptor,” The Journal of Biological Chemistry, vol. 275, no. 52, pp. 40742–40748, 2000. View at Publisher · View at Google Scholar · View at Scopus
  61. C. Stross, S. Radtke, T. Clahsen et al., “Oncostatin M receptor-mediated signal transduction is negatively regulated by SOCS3 through a receptor tyrosine-independent mechanism,” The Journal of Biological Chemistry, vol. 281, no. 13, pp. 8458–8468, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. L. Tong, D. Smyth, C. Kerr, J. Catterall, and C. D. Richards, “Mitogen-activated protein kinases Erk1/2 and p38 are required for maximal regulation of TIMP-1 by oncostatin M in murine fibroblasts,” Cellular Signalling, vol. 16, no. 10, pp. 1123–1132, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. D. K. Fritz, C. Kerr, L. Tong, D. Smyth, and C. D. Richards, “Oncostatin-M up-regulates VCAM-1 and synergizes with IL-4 in eotaxin expression: involvement of STAT6,” The Journal of Immunology, vol. 176, no. 7, pp. 4352–4360, 2006. View at Google Scholar · View at Scopus
  64. D. C. Smyth, C. Kerr, and C. D. Richards, “Oncostatin M-induced IL-6 expression in murine fibroblasts requires the activation of protein kinase Cδ,” The Journal of Immunology, vol. 177, no. 12, pp. 8740–8747, 2006. View at Google Scholar · View at Scopus
  65. C. Diveu, A.-H. L. Lak-Hal, J. Froger et al., “Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling,” European Cytokine Network, vol. 15, no. 4, pp. 291–302, 2004. View at Google Scholar · View at Scopus
  66. S. Chattopadhyay, E. Tracy, P. Liang, O. Robledo, S. Rose-John, and H. Baumann, “Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells,” The Journal of Biological Chemistry, vol. 282, no. 5, pp. 3014–3026, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. R. S. Jawa, S. Chattopadhyay, E. Tracy et al., “Regulated expression of the IL-31 receptor in bronchial and alveolar epithelial cells, pulmonary fibroblasts, and pulmonary macrophages,” Journal of Interferon and Cytokine Research, vol. 28, no. 4, pp. 207–219, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. J. Bilsborough, D. Y. M. Leung, M. Maurer et al., “IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis,” Journal of Allergy and Clinical Immunology, vol. 117, no. 2, pp. 418–425, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Nobbe, P. Dziunycz, B. Mühleisen et al., “IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis,” Acta Dermato-Venereologica, vol. 92, no. 1, pp. 24–28, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. J. G. Perrigoue, J. Li, C. Zaph et al., “IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung,” Journal of Experimental Medicine, vol. 204, no. 3, pp. 481–487, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. J. Bilsborough, S. Mudri, E. Chadwick, B. Harder, and S. R. Dillon, “IL-31 receptor (IL-31RA) knockout mice exhibit elevated responsiveness to oncostatin M,” The Journal of Immunology, vol. 185, no. 10, pp. 6023–6030, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. C. Diveu, E. Venereau, J. Froger et al., “Molecular and functional characterization of a soluble form of oncostatin M/interleukin-31 shared receptor,” The Journal of Biological Chemistry, vol. 281, no. 48, pp. 36673–36682, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. T. Jostock, J. Müllberg, S. Özbek et al., “Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses,” European Journal of Biochemistry, vol. 268, no. 1, pp. 160–167, 2001. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Rose-John and P. C. Heinrich, “Soluble receptors for cytokines and growth factors: generation and biological function,” Biochemical Journal, vol. 300, no. 2, pp. 281–290, 1994. View at Google Scholar · View at Scopus
  75. L. Brolund, A. Küster, S. Korr, M. Vogt, and G. Müller-Newen, “A receptor fusion protein for the inhibition of murine oncostatin M,” BMC Biotechnology, vol. 11, article 3, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. N. Malik, H. S. Haugen, B. Modrell, M. Shoyab, and C. H. Clegg, “Developmental abnormalities in mice transgenic for bovine oncostatin M,” Molecular and Cellular Biology, vol. 15, no. 5, pp. 2349–2358, 1995. View at Google Scholar · View at Scopus
  77. B. Bamber, R. A. Reife, H. S. Haugen, and C. H. Clegg, “Oncostatin M stimulates excessive extracellular matrix accumulation in a transgenic mouse model of connective tissue disease,” Journal of Molecular Medicine, vol. 76, no. 1, pp. 61–69, 1998. View at Google Scholar · View at Scopus
  78. C. H. Clegg, J. T. Rulffes, P. M. Wallace, and H. S. Haugen, “Regulation of an extrathymic T-cell development pathway by oncostatin M,” Nature, vol. 384, no. 6606, pp. 261–263, 1996. View at Publisher · View at Google Scholar · View at Scopus
  79. F. M. Botelho, J. Rangel-Moreno, D. Fritz, T. D. Randall, Z. Xing, and C. D. Richards, “Pulmonary expression of oncostatin M, (OSM) promotes inducible BALT formation independently of IL-6, despite a role for IL-6 in OSM-driven pulmonary inflammation,” The Journal of Immunology, vol. 191, no. 3, pp. 1453–1464, 2013. View at Publisher · View at Google Scholar
  80. Y. Morikawa, S. Tamura, K.-I. Minehata, P. J. Donovan, A. Miyajima, and E. Senba, “Essential function of oncostatin M in nociceptive neurons of dorsal root ganglia,” Journal of Neuroscience, vol. 24, no. 8, pp. 1941–1947, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. E. Esashi, H. Ito, K.-I. Minehata, S. Saito, Y. Morikawa, and A. Miyajima, “Oncostatin M deficiency leads to thymic hypoplasia, accumulation of apoptotic thymocytes and glomerulonephritis,” European Journal of Immunology, vol. 39, no. 6, pp. 1664–1670, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. C. H. Clegg, H. S. Haugen, J. T. Rulffes, S. L. Friend, and A. G. Farr, “Oncostatin M transforms lymphoid tissue function in transgenic mice by stimulating lymph node T-cell development and thymus autoantibody production,” Experimental Hematology, vol. 27, no. 4, pp. 712–725, 1999. View at Publisher · View at Google Scholar · View at Scopus
  83. M. Tanaka, Y. Hirabayashi, T. Sekiguchi, T. Inoue, M. Katsuki, and A. Miyajima, “Targeted disruption of oncostatin M receptor results in altered hematopoiesis,” Blood, vol. 102, no. 9, pp. 3154–3162, 2003. View at Publisher · View at Google Scholar · View at Scopus
  84. E. Hams, C. S. Colmont, V. Dioszeghy et al., “Oncostatin M receptor-β signaling limits monocytic cell recruitment in acute inflammation,” The Journal of Immunology, vol. 181, no. 3, pp. 2174–2180, 2008. View at Google Scholar · View at Scopus
  85. K. Nakamura, H. Nonaka, H. Saito, M. Tanaka, and A. Miyajima, “Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice,” Hepatology, vol. 39, no. 3, pp. 635–644, 2004. View at Publisher · View at Google Scholar · View at Scopus
  86. E. C. Walker, N. E. McGregor, I. J. Poulton et al., “Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice mice,” The Journal of Clinical Investigation, vol. 120, no. 2, pp. 582–592, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. T. Komori, M. Tanaka, E. Senba, A. Miyajima, and Y. Morikawa, “Lack of oncostatin M receptor beta Leads to adipose tissue inflammation and insulin resistance by switching macrophage phenotype,” The Journal of Biological Chemistry, vol. 288, pp. 21861–21875, 2013. View at Publisher · View at Google Scholar
  88. H. Baumann and J. Gauldie, “The acute phase response,” Immunology Today, vol. 15, no. 2, pp. 74–80, 1994. View at Publisher · View at Google Scholar · View at Scopus
  89. C. D. Richards, T. J. Brown, M. Shoyab, H. Baumann, and J. Gauldie, “Recombinant oncostatin M stimulates the production of acute phase proteins in HepG2 cells and rat primary hepatocytes in vitro,” The Journal of Immunology, vol. 148, no. 6, pp. 1731–1736, 1992. View at Google Scholar · View at Scopus
  90. R. I. Grove, C. E. Mazzucco, S. F. Radka, M. Shoyab, and P. A. Kiener, “Oncostatin M up-regulates low density lipoprotein receptors in HepG2 cells by a novel mechanism,” The Journal of Biological Chemistry, vol. 266, no. 27, pp. 18194–18199, 1991. View at Google Scholar · View at Scopus
  91. J. Kanda, T. Uchiyama, N. Tomosugi, M. Higuchi, T. Uchiyama, and H. Kawabata, “Oncostatin M and leukemia inhibitory factor increase hepcidin expression in hepatoma cell lines,” International Journal of Hematology, vol. 90, no. 5, pp. 545–552, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. B. Chung, F. Verdier, P. Matak, J.-C. Deschemin, P. Mayeux, and S. Vaulont, “Oncostatin M is a potent inducer of hepcidin, the iron regulatory hormone,” FASEB Journal, vol. 24, no. 6, pp. 2093–2103, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. A. Miyajima, T. Kinoshita, M. Tanaka, A. Kamiya, Y. Mukouyama, and T. Hara, “Role of oncostatin M in hematopoiesis and liver development,” Cytokine and Growth Factor Reviews, vol. 11, no. 3, pp. 177–183, 2000. View at Publisher · View at Google Scholar · View at Scopus
  94. T. Hamada, A. Sato, T. Hirano et al., “Oncostatin M gene therapy attenuates liver damage induced by dimethylnitrosamine in rats,” American Journal of Pathology, vol. 171, no. 3, pp. 872–881, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. D. A. Mann and F. Marra, “Fibrogenic signalling in hepatic stellate cells,” Journal of Hepatology, vol. 52, no. 6, pp. 949–950, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. I. Znoyko, N. Sohara, S. S. Spicer, M. Trojanowska, and A. Reuben, “Expression of oncostatin M and its receptors in normal and cirrhotic human liver,” Journal of Hepatology, vol. 43, no. 5, pp. 893–900, 2005. View at Publisher · View at Google Scholar · View at Scopus
  97. T. Tanaka, M. Narazaki, and T. Kishimoto, “Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases,” FEBS Letters, vol. 585, no. 23, pp. 3699–3709, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. T. E. Cawston, V. A. Curry, C. A. Summers et al., “The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint,” Arthritis & Rheumatism, vol. 41, pp. 1760–1771, 1998. View at Google Scholar
  99. C. Langdon, J. Leith, F. Smith, and C. D. Richards, “Oncostatin M stimulates monocyte chemoattractant protein-1- and interleukin-1-induced matrix metalloproteinase-1 production by human synovial fibroblasts in vitro,” Arthritis and Rheumatism, vol. 40, no. 12, pp. 2139–2146, 1997. View at Publisher · View at Google Scholar · View at Scopus
  100. W. Hui, M. Bell, and G. Carroll, “Detection of oncostatin M in synovial fluid from patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 56, no. 3, pp. 184–187, 1997. View at Google Scholar · View at Scopus
  101. C. D. Richards, M. Shoyab, T. J. Brown, and J. Gauldie, “Selective regulation of metalloproteinase inhibitor (TIMP-1) by oncostatin M in fibroblasts in culture,” The Journal of Immunology, vol. 150, no. 12, pp. 5596–5603, 1993. View at Google Scholar · View at Scopus
  102. W. Q. Li and M. Zafarullah, “Oncostatin M up-regulates tissue inhibitor of metalloproteinases-3 gene expression in articular chondrocytes viade novo transcription, protein synthesis, and tyrosine kinase- and mitogen-activated protein kinase- dependent mechanisms,” The Journal of Immunology, vol. 161, no. 9, pp. 5000–5007, 1998. View at Google Scholar · View at Scopus
  103. C. Langdon, C. Kerr, M. Hassen, T. Hara, A. L. Arsenault, and C. D. Richards, “Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo,” American Journal of Pathology, vol. 157, no. 4, pp. 1187–1196, 2000. View at Google Scholar · View at Scopus
  104. C. Hintzen, S. Quaiser, T. Pap, P. C. Heinrich, and H. M. Hermanns, “Induction of CCL13 expression in synovial fibroblasts highlights a significant role of oncostatin M in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 60, no. 7, pp. 1932–1943, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. T. Cawston, C. Billington, C. Cleaver et al., “The regulation of MMPs and TIMPs in cartilage turnover,” Annals of the New York Academy of Sciences, vol. 878, pp. 120–129, 1999. View at Publisher · View at Google Scholar · View at Scopus
  106. A. D. Rowan, P. J. Koshy, W. D. Shingleton et al., “Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown,” Arthritis & Rheumatism, vol. 44, pp. 1620–1632, 2001. View at Google Scholar
  107. P. J. T. Koshy, C. J. Lundy, A. D. Rowan et al., “The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction,” Arthritis and Rheumatism, vol. 46, no. 4, pp. 961–967, 2002. View at Publisher · View at Google Scholar · View at Scopus
  108. H. E. Barksby, W. Hui, I. Wappler et al., “Interleukin-1 in combination with oncostatin M up-regulates multiple genes in chondrocytes: implications for cartilage destruction and repair,” Arthritis and Rheumatism, vol. 54, no. 2, pp. 540–550, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. P. J. Koshy, N. Henderson, C. Logan, P. F. Life, T. E. Cawston, and A. D. Rowan, “Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines,” Annals of the Rheumatic Diseases, vol. 61, no. 8, pp. 704–713, 2002. View at Publisher · View at Google Scholar · View at Scopus
  110. C. Plater-Zyberk, J. Buckton, S. Thompson et al., “Amelioration of arthritis in two murine models using antibodies to oncostatin M,” Arthritis Rheum, vol. 44, pp. 2697–2702, 2001. View at Google Scholar
  111. P. M. Wallace, J. F. MacMaster, K. A. Rouleau et al., “Erratum: Regulation of inflammatory responses by oncostatin M,” The Journal of Immunology, vol. 164, no. 10, p. 5531, 2000. View at Google Scholar · View at Scopus
  112. P. M. Wallace, J. F. MacMaster, K. A. Rouleau et al., “Erratum: regulation of inflammatory responses by oncostatin M,” The Journal of Immunology, vol. 164, no. 10, p. 5531, 2000. View at Google Scholar · View at Scopus
  113. C. H. Clegg, H. S. Haugen, J. T. Rulffes, S. L. Friend, and A. G. Farr, “Oncostatin M transforms lymphoid tissue function in transgenic mice by stimulating lymph node T-cell development and thymus autoantibody production,” Experimental Hematology, vol. 27, no. 4, pp. 712–725, 1999. View at Publisher · View at Google Scholar · View at Scopus
  114. T. S.-C. Juan, B. Bolon, R. A. Lindberg, Y. Sun, V. G. Van G, and F. A. Fletcher, “Mice overexpressing murine oncostatin m (osm) exhibit changes in hematopoietic and other organs that are distinct from those of mice overexpressing human OSM or bovine OSM,” Veterinary Pathology, vol. 46, no. 1, pp. 124–137, 2009. View at Publisher · View at Google Scholar · View at Scopus
  115. E. Lubberts, L. A. B. Joosten, M. Chabaud et al., “IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion,” The Journal of Clinical Investigation, vol. 105, no. 12, pp. 1697–1710, 2000. View at Google Scholar · View at Scopus
  116. E. Lubberts, L. A. B. Joosten, L. Van Den Bersselaar et al., “Intra-articular IL-10 gene transfer regulates the expression of collagen-induced arthritis (CIA) in the knee and ipsilateral paw,” Clinical and Experimental Immunology, vol. 120, no. 2, pp. 375–383, 2000. View at Publisher · View at Google Scholar · View at Scopus
  117. A. S. K. De Hooge, F. A. J. Van de Loo, M. B. Bennink et al., “Growth plate damage, a feature of juvenile idiopathic arthritis, can be induced by adenoviral gene transfer of oncostatin M: a comparative study in gene-deficient mice,” Arthritis and Rheumatism, vol. 48, no. 6, pp. 1750–1761, 2003. View at Publisher · View at Google Scholar · View at Scopus
  118. A. Rowan, W. Hui, T. E. Cawston, and C. D. Richards, “Adenoviral gene transfer of interleukin-1 in combination with oncostatin M induces significant joint damage in a murine model,” American Journal of Pathology, vol. 162, no. 6, pp. 1975–1984, 2003. View at Google Scholar · View at Scopus
  119. W. Hui, T. E. Cawston, C. D. Richards, and A. D. Rowan, “A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKL,” Arthritis Research & Therapy, vol. 7, no. 1, pp. R57–64, 2005. View at Google Scholar · View at Scopus
  120. W. Hui, A. D. Rowan, C. D. Richards, and T. E. Cawston, “Oncostatin M in combination with tumor necrosis factor α induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo,” Arthritis and Rheumatism, vol. 48, no. 12, pp. 3404–3418, 2003. View at Publisher · View at Google Scholar · View at Scopus
  121. H. E. Barksby, J. M. Milner, A. M. Patterson et al., “Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degradation in arthritis,” Arthritis and Rheumatism, vol. 54, no. 10, pp. 3244–3253, 2006. View at Publisher · View at Google Scholar · View at Scopus
  122. J. M. Milner, L. Kevorkian, D. A. Young et al., “Fibroblast activation protein alpha is expressed by chondrocytes following a pro-inflammatory stimulus and is elevated in osteoarthritis,” Arthritis Research and Therapy, vol. 8, no. 1, article R23, 2006. View at Publisher · View at Google Scholar · View at Scopus
  123. G. J. Litherland, C. Dixon, R. L. Lakey et al., “Synergistic collagenase expression and cartilage collagenolysis are phosphatidylinositol 3-kinase/Akt signaling-dependent,” The Journal of Biological Chemistry, vol. 283, no. 21, pp. 14221–14229, 2008. View at Publisher · View at Google Scholar · View at Scopus
  124. S. J. Gilbert, E. J. Blain, A. Al-Sabah, Y. Zhang, V. C. Duance, and D. J. Mason, “Protein kinase R plays a pivotal role in oncostatin M and interleukin-1 signalling in bovine articular cartilage chondrocytes,” European Cells and Materials, vol. 23, pp. 41–57, 2012. View at Google Scholar · View at Scopus
  125. T. Tanaka, M. Narazaki, and T. Kishimoto, “Therapeutic targeting of the interleukin-6 receptor,” Annual Review of Pharmacology and Toxicology, vol. 52, pp. 199–219, 2012. View at Publisher · View at Google Scholar · View at Scopus
  126. D. Heymann and A.-V. Rousselle, “gp130 cytokine family and bone cells,” Cytokine, vol. 12, no. 10, pp. 1455–1468, 2000. View at Publisher · View at Google Scholar · View at Scopus
  127. P. R. Jay, M. Centrella, J. Lorenzo, A. G. Bruce, and M. C. Horowitz, “Oncostatin-M: a new bone active cytokine that activates osteoblasts and inhibits bone resorption,” Endocrinology, vol. 137, no. 4, pp. 1151–1158, 1996. View at Publisher · View at Google Scholar · View at Scopus
  128. T. Bellido, N. Stahl, T. J. Farruggella, V. Borba, G. D. Yancopoulos, and S. C. Manolagas, “Detection of receptors for lnterleukin-6, lnterleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells,” The Journal of Clinical Investigation, vol. 97, no. 2, pp. 431–437, 1996. View at Google Scholar · View at Scopus
  129. Y. Taguchi, M. Yamamoto, T. Yamate et al., “Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage,” Proceedings of the Association of American Physicians, vol. 110, no. 6, pp. 559–574, 1998. View at Google Scholar · View at Scopus
  130. F. Liu, J. E. Aubin, and L. Malaval, “Expression of leukemia inhibitory factor (LIF)/interleukin-6 family cytokines and receptors during in vitro osteogenesis: differential regulation by dexamethasone and LIF,” Bone, vol. 31, no. 1, pp. 212–219, 2002. View at Publisher · View at Google Scholar · View at Scopus
  131. L. Malaval, F. Liu, A. B. Vernallis, and J. E. Aubin, “GP130/OSMR is the only LIF/IL-6 family receptor complex to promote osteoblast differentiation of calvaria progenitors,” Journal of Cellular Physiology, vol. 204, no. 2, pp. 585–593, 2005. View at Publisher · View at Google Scholar · View at Scopus
  132. A. S. K. De Hooge, F. A. J. Van De Loo, M. B. Bennink et al., “Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-κB ligand,” American Journal of Pathology, vol. 160, no. 5, pp. 1733–1743, 2002. View at Google Scholar · View at Scopus
  133. P. Guihard, Y. Danger, B. Brounais et al., “Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling,” Stem Cells, vol. 30, no. 4, pp. 762–772, 2012. View at Publisher · View at Google Scholar · View at Scopus
  134. E. C. Walker, I. J. Poulton, N. E. McGregor et al., “Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo,” Journal of Bone and Mineral Research, vol. 27, no. 4, pp. 902–912, 2012. View at Publisher · View at Google Scholar · View at Scopus
  135. T. J. Fernandes, J. M. Hodge, P. P. Singh et al., “Cord blood-derived macrophage-lineage cells rapidly stimulate osteoblastic maturation in mesenchymal stem cells in a glycoprotein-130 dependent manner,” PLoS ONE, vol. 8, Article ID e73266, 2013. View at Publisher · View at Google Scholar
  136. V. Nicolaidou, M. M. Wong, A. N. Redpath et al., “Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation,” PLoS ONE, vol. 7, no. 7, Article ID e39871, 2012. View at Publisher · View at Google Scholar
  137. S.-H. Kok, C.-Y. Hong, M. Y.-P. Kuo et al., “Oncostatin M-induced CCL2 transcription in osteoblastic cells is mediated by multiple levels of STAT-1 and STAT-3 signaling: an implication for the pathogenesis of arthritis,” Arthritis and Rheumatism, vol. 60, no. 5, pp. 1451–1462, 2009. View at Publisher · View at Google Scholar · View at Scopus
  138. C. D. Richards, C. Langdon, P. Deschamps, D. Pennica, and S. G. Shaughnessy, “Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone,” Cytokine, vol. 12, no. 6, pp. 613–621, 2000. View at Publisher · View at Google Scholar · View at Scopus
  139. P. Palmqvist, E. Persson, H. H. Conaway, and U. H. Lerner, “IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-κB ligand, osteoprotegerin, and receptor activator of NF-κB in mouse calvariae,” The Journal of Immunology, vol. 169, no. 6, pp. 3353–3362, 2002. View at Google Scholar · View at Scopus
  140. I. Kawashima and Y. Takiguchi, “Interleukin-11: a novel stroma-derived cytokine,” Cytokine and Growth Factor Reviews, vol. 4, no. 3, pp. 191–204, 1992. View at Google Scholar · View at Scopus
  141. D. C. Keller, X. X. Du, E. F. Srour, R. Hoffman, and D. A. Williams, “Interleukin-11 inhibits adipogenesis and stimulates myelopoiesis in human long-term marrow cultures,” Blood, vol. 82, no. 5, pp. 1428–1435, 1993. View at Google Scholar · View at Scopus
  142. J. Ohsumi, K. Miyadai, I. Kawashima, S. Sakakibara, J. Yamaguchi, and Y. Itoh, “Regulation of lipoprotein lipase synthesis in 3T3-L1 adipocytes by interleukin-11/adipogenesis inhibitory factor,” Biochemistry and Molecular Biology International, vol. 32, no. 4, pp. 705–712, 1994. View at Google Scholar · View at Scopus
  143. N. Yanai and M. Obinata, “Oncostatin M regulates mesenchymal cell differentiation and enhances hematopoietic supportive activity of bone marrow stromal cell lines,” In Vitro Cellular and Developmental Biology, vol. 37, no. 10, pp. 698–704, 2001. View at Google Scholar · View at Scopus
  144. Y. S. Hae, S. J. Eun, I. K. Jung, S. J. Jin, and H. K. Jae, “Oncostatin M promotes osteogenesis and suppresses adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells,” Journal of Cellular Biochemistry, vol. 101, no. 5, pp. 1238–1251, 2007. View at Publisher · View at Google Scholar · View at Scopus
  145. Y. Miyaoka, M. Tanaka, T. Naiki, and A. Miyajima, “Oncostatin M inhibits adipogenesis through the RAS/ERK and STAT5 signaling pathways,” The Journal of Biological Chemistry, vol. 281, no. 49, pp. 37913–37920, 2006. View at Publisher · View at Google Scholar · View at Scopus
  146. S. Zvonic, J. E. Baugh Jr., P. Arbour-Reily, R. L. Mynatt, and J. M. Stephens, “Cross-talk among gp130 cytokines in adipocytes,” The Journal of Biological Chemistry, vol. 280, no. 40, pp. 33856–33863, 2005. View at Publisher · View at Google Scholar · View at Scopus
  147. A. S. Hamilton, S. F. Radka, L. Bernstein et al., “Relationship of serum levels of oncostatin M to AIDS-related and classic Kaposi's sarcoma,” Journal of Acquired Immune Deficiency Syndromes, vol. 7, no. 4, pp. 410–414, 1994. View at Google Scholar · View at Scopus
  148. P. M. Wallace, J. F. MacMaster, K. A. Rouleau et al., “Erratum: regulation of inflammatory responses by oncostatin M,” The Journal of Immunology, vol. 164, no. 10, p. 5531, 2000. View at Google Scholar · View at Scopus
  149. M. C. Amaral, S. Miles, G. Kumar, and A. E. Nel, “Oncostatin-M stimulates tyrosine protein phosphorylation in parallel with the activation of p42(MAPK)/ERK-2 in Kaposi's cells: evidence that this pathway is important in Kaposi cell growth,” The Journal of Clinical Investigation, vol. 92, no. 2, pp. 848–857, 1993. View at Google Scholar · View at Scopus
  150. A. Lacreusette, J.-M. Nguyen, M.-C. Pandolfino et al., “Loss of oncostatin M receptor β in metastatic melanoma cells,” Oncogene, vol. 26, no. 6, pp. 881–892, 2007. View at Publisher · View at Google Scholar · View at Scopus
  151. W. Komyod, M. Böhm, D. Metze, P. C. Heinrich, and I. Behrmann, “Constitutive suppressor of cytokine signaling 3 expression confers a growth advantage to a human melanoma cell line,” Molecular Cancer Research, vol. 5, no. 3, pp. 271–281, 2007. View at Publisher · View at Google Scholar · View at Scopus
  152. A. Lacreusette, A. Lartigue, J.-M. Nguyen et al., “Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes,” Journal of Pathology, vol. 216, no. 4, pp. 451–459, 2008. View at Publisher · View at Google Scholar · View at Scopus
  153. A. Lacreusette, I. Barbieux, J.-M. Nguyen et al., “Defective activations of STAT3 Ser727 and PKC isoforms lead to oncostatin M resistance in metastatic melanoma,” Journal of Pathology, vol. 217, no. 5, pp. 665–676, 2009. View at Publisher · View at Google Scholar · View at Scopus
  154. K. Mori, F. Rédini, F. Gouin, B. Cherrier, and D. Heymann, “Osteosarcoma: current status of immunotherapy and future trends (Review),” Oncology Reports, vol. 15, no. 3, pp. 693–700, 2006. View at Google Scholar · View at Scopus
  155. C. Chipoy, M. Berreur, S. Couillaud et al., “Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCδ and STAT3,” Journal of Bone and Mineral Research, vol. 19, no. 11, pp. 1850–1861, 2004. View at Publisher · View at Google Scholar · View at Scopus
  156. C. Chipoy, B. Brounais, V. Trichet et al., “Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53,” Oncogene, vol. 26, no. 46, pp. 6653–6664, 2007. View at Publisher · View at Google Scholar · View at Scopus
  157. B. Brounais, E. David, C. Chipoy et al., “Long term oncostatin M treatment induces an osteocyte-like differentiation on osteosarcoma and calvaria cells,” Bone, vol. 44, no. 5, pp. 830–839, 2009. View at Publisher · View at Google Scholar · View at Scopus
  158. B. Brounais, C. Chipoy, K. Mori et al., “Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the antitumor effect of midostaurin in vivo,” Clinical Cancer Research, vol. 14, no. 17, pp. 5400–5409, 2008. View at Publisher · View at Google Scholar · View at Scopus
  159. S. L. Fossey, M. D. Bear, W. C. Kisseberth, M. Pennell, and C. A. London, “Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines,” BMC Cancer, vol. 11, article 125, 2011. View at Publisher · View at Google Scholar · View at Scopus
  160. A. M. Douglas, G. A. Goss, R. L. Sutherland et al., “Expression and function of members of the cytokine receptor superfamily on breast cancer cells,” Oncogene, vol. 14, no. 6, pp. 661–669, 1997. View at Google Scholar · View at Scopus
  161. I. García-Tuñón, M. Ricote, A. Ruiz, B. Fraile, R. Paniagua, and M. Royuela, “OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative),” Cancer Investigation, vol. 26, no. 3, pp. 222–229, 2008. View at Publisher · View at Google Scholar · View at Scopus
  162. N. R. West, L. C. Murphy, and P. H. Watson, “Oncostatin M suppresses oestrogen receptor-alpha expression and is associated with poor outcome in human breast cancer,” Endocrine-Related Cancer, vol. 19, pp. 181–195, 2012. View at Google Scholar
  163. C. Li, F. Zhang, M. Lin, and J. Liu, “Induction of S100A9 gene expression by cytokine oncostatin M in breast cancer cells through the STAT3 signaling cascade,” Breast Cancer Research and Treatment, vol. 87, no. 2, pp. 123–134, 2004. View at Publisher · View at Google Scholar · View at Scopus
  164. N. R. West and P. H. Watson, “S100A7 (psoriasin) is induced by the proinflammatory cytokines oncostatin-M and interleukin-6 in human breast cancer,” Oncogene, vol. 29, no. 14, pp. 2083–2092, 2010. View at Publisher · View at Google Scholar · View at Scopus
  165. R. G. Holzer, R. E. Ryan, M. Tommack, E. Schlekeway, and C. L. Jorcyk, “Oncostatin M stimulates the detachment of a reservoir of invasive mammary carcinoma cells: role of cyclooxygenase-2,” Clinical and Experimental Metastasis, vol. 21, no. 2, pp. 167–176, 2004. View at Publisher · View at Google Scholar · View at Scopus
  166. C. L. Jorcyk, R. G. Holzer, and R. E. Ryan, “Oncostatin M induces cell detachment and enhances the metastatic capacity of T-47D human breast carcinoma cells,” Cytokine, vol. 33, no. 6, pp. 323–336, 2006. View at Publisher · View at Google Scholar · View at Scopus
  167. M. Snyder, X.-Y. Huang, and J. J. Zhang, “Signal Transducers and Activators of Transcription 3 (STAT3) directly regulates cytokine-induced fascin expression and is required for breast cancer cell migration,” The Journal of Biological Chemistry, vol. 286, no. 45, pp. 38886–38893, 2011. View at Publisher · View at Google Scholar · View at Scopus
  168. C. E. Kan, R. Cipriano, and M. W. Jackson, “c-MYC functions as a molecular switch to alter the response of human mammary epithelial cells to oncostatin M,” Cancer Research, vol. 71, no. 22, pp. 6930–6939, 2011. View at Publisher · View at Google Scholar · View at Scopus
  169. E. David, P. Guihard, B. Brounais et al., “Direct anti-cancer effect of oncostatin M on chondrosarcoma,” International Journal of Cancer, vol. 128, no. 8, pp. 1822–1835, 2011. View at Publisher · View at Google Scholar · View at Scopus
  170. E. David, F. Tirode, M. Baud'huin et al., “Oncostatin M is a growth factor for Ewing sarcoma,” American Journal of Pathology, vol. 181, pp. 1782–1795, 2012. View at Google Scholar
  171. N. R. West, J. I. Murray, and P. H. Watson, “Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer,” Oncogene, 2013. View at Publisher · View at Google Scholar
  172. L. Guo, C. Chen, M. Shi et al., “Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition,” Oncogene, 2013. View at Publisher · View at Google Scholar
  173. Q. Li, J. Zhu, F. Sun, L. Liu, X. Liu, and Y. Yue, “Oncostatin M promotes proliferation of ovarian cancer cells through signal transducer and activator of transcription 3,” International Journal of Molecular Medicine, vol. 28, no. 1, pp. 101–108, 2011. View at Publisher · View at Google Scholar · View at Scopus
  174. G. Ng, D. Winder, B. Muralidhar et al., “Gain and overexpression of the oncostatin M receptor occur frequently in cervical squamous cell carcinoma and are associated with adverse clinical outcome,” Journal of Pathology, vol. 212, no. 3, pp. 325–334, 2007. View at Publisher · View at Google Scholar · View at Scopus
  175. D. M. Winder, A. Chattopadhyay, B. Muralidhar et al., “Overexpression of the oncostatin M receptor in cervical squamous cell carcinoma cells is associated with a pro-angiogenic phenotype and increased cell motility and invasiveness,” Journal of Pathology, vol. 225, no. 3, pp. 448–462, 2011. View at Publisher · View at Google Scholar · View at Scopus
  176. A. Krona, S. Järnum, L. G. Salford, B. Widegren, and P. Aman, “Oncostatin M signaling in human glioma cell lines,” Oncology reports, vol. 13, no. 5, pp. 807–811, 2005. View at Google Scholar · View at Scopus
  177. S.-H. Chen, G. Y. Gillespie, and E. N. Benveniste, “Divergent effects of oncostatin M on astroglioma cells: Influence on cell proliferation, invasion, and expression of matrix metalloproteinases,” GLIA, vol. 53, no. 2, pp. 191–200, 2006. View at Publisher · View at Google Scholar · View at Scopus
  178. S. Godoy-Tundidor, I. T. R. Cavarretta, D. Fuchs et al., “Interleukin-6 and Oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase,” Prostate, vol. 64, no. 2, pp. 209–216, 2005. View at Publisher · View at Google Scholar · View at Scopus
  179. T. W. Weiss, R. Simak, C. Kaun et al., “Oncostatin M and IL-6 induce u-PA and VEGF in prostate cancer cells and correlate in vivo,” Anticancer Research, vol. 31, no. 10, pp. 3273–3278, 2011. View at Google Scholar · View at Scopus
  180. M. Royuela, M. Ricote, M. S. Parsons, I. García-Tuñón, R. Paniagua, and M. P. De Miguel, “Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic and malignant human prostate,” Journal of Pathology, vol. 202, no. 1, pp. 41–49, 2004. View at Publisher · View at Google Scholar · View at Scopus
  181. D. A. Smith, A. Kiba, Y. Zong, and O. N. Witte, “Interleukin-6 and oncostatin-M synergize with the PI3K/AKT pathway to promote aggressive prostate malignancy in mouse and human tissues,” Molecular Cancer Research, vol. 11, no. 10, pp. 1159–1165, 2013. View at Publisher · View at Google Scholar
  182. G. M. Loewen, E. Tracy, F. Blanchard et al., “Transformation of human bronchial epithelial cells alters responsiveness to inflammatory cytokines,” BMC Cancer, vol. 5, article 145, 2005. View at Publisher · View at Google Scholar · View at Scopus
  183. G. M. Argast, P. Mercado, I. J. Mulford et al., “Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-β enhances epithelial to mesenchymal transition in lung and pancreatic tumor models,” Cells Tissues Organs, vol. 193, no. 1-2, pp. 114–132, 2010. View at Publisher · View at Google Scholar · View at Scopus
  184. M. L. Wang, C. M. Pan, S. H. Chiou et al., “Oncostatin m modulates the mesenchymal-epithelial transition of lung adenocarcinoma cells by a mesenchymal stem cell-mediated paracrine effect,” Cancer Research, vol. 72, pp. 6051–6064, 2012. View at Google Scholar
  185. D. R. Chen, C.-Y. Chu, C.-Y. Chen et al., “Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas,” Journal of Pathology, vol. 215, no. 3, pp. 290–299, 2008. View at Publisher · View at Google Scholar · View at Scopus
  186. M. S. Kim, J. Louwagie, B. Carvalho et al., “Promoter DNA methylation of Oncostatin M receptor-β as a novel diagnostic and therapeutic marker in colon cancer,” PLoS ONE, vol. 4, no. 8, Article ID e6555, 2009. View at Publisher · View at Google Scholar · View at Scopus
  187. G. Deng, S. Kakar, K. Okudiara, E. Choi, M. H. Sleisenger, and Y. S. Kim, “Unique methylation pattern of oncostatin M receptor gene in cancers of colorectum and other digestive organs,” Clinical Cancer Research, vol. 15, no. 5, pp. 1519–1526, 2009. View at Publisher · View at Google Scholar · View at Scopus
  188. K. Hibi, T. Goto, K. Sakuraba et al., “Methylation of OSMR gene is frequently observed in non-invasive colorectal cancer,” Anticancer Research, vol. 31, no. 4, pp. 1293–1295, 2011. View at Google Scholar · View at Scopus
  189. T. Kausar, R. Sharma, M. R. Hasan et al., “Overexpression of a splice variant of oncostatin M receptor beta in human esophageal squamous carcinoma,” Cellular Oncology, vol. 34, no. 3, pp. 177–187, 2011. View at Google Scholar · View at Scopus
  190. I. K. Hong, Y. G. Eun, D. H. Chung, K. H. Kwon, and D. Y. Kim, “Association of the oncostatin M receptor gene polymorphisms with papillary thyroid cancer in the Korean population,” Clinical and Experimental Otorhinolaryngology, vol. 4, no. 4, pp. 193–198, 2011. View at Publisher · View at Google Scholar · View at Scopus
  191. B. Engels, D. A. Rowley, and H. Schreiber, “Targeting stroma to treat cancers,” Seminars in Cancer Biology, vol. 22, no. 1, pp. 41–49, 2012. View at Publisher · View at Google Scholar · View at Scopus
  192. K. Räsänen and A. Vaheri, “Activation of fibroblasts in cancer stroma,” Experimental Cell Research, vol. 316, no. 17, pp. 2713–2722, 2010. View at Publisher · View at Google Scholar · View at Scopus
  193. K. Pietras and A. Östman, “Hallmarks of cancer: interactions with the tumor stroma,” Experimental Cell Research, vol. 316, no. 8, pp. 1324–1331, 2010. View at Publisher · View at Google Scholar · View at Scopus
  194. M. M. Queen, R. E. Ryan, R. G. Holzer, C. R. Keller-Peck, and C. L. Jorcyk, “Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression,” Cancer Research, vol. 65, no. 19, pp. 8896–8904, 2005. View at Publisher · View at Google Scholar · View at Scopus
  195. P. Vlaicu, P. Mertins, T. Mayr et al., “Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator,” BMC Cancer, vol. 13, p. 197, 2013. View at Publisher · View at Google Scholar
  196. C. Bolin, K. Tawara, C. Sutherland et al., “Oncostatin m promotes mammary tumor metastasis to bone and osteolytic bone degradation,” Genes Cancer, vol. 3, pp. 117–130, 2012. View at Google Scholar
  197. D. D. Benson, X. Meng, D. A. Fullerton et al., “Activation state of stromal inflammatory cells in murine metastatic pancreatic adenocarcinoma,” American Journal of Physiology, vol. 302, no. 9, pp. R1067–R1075, 2012. View at Publisher · View at Google Scholar · View at Scopus
  198. K. Ruprecht, T. Kuhlmann, F. Seif et al., “Effects of oncostatin M on human cerebral endothelial cells and expression in inflammatory brain lesions,” Journal of Neuropathology and Experimental Neurology, vol. 60, no. 11, pp. 1087–1098, 2001. View at Google Scholar · View at Scopus
  199. N. J. Van Wagoner, C. Choi, P. Repovic, and E. N. Benveniste, “Oncostatin M regulation of interleukin-6 expression in astrocytes: biphasic regulation involving the mitogen-activated protein kinases ERK1/2 and p38,” Journal of Neurochemistry, vol. 75, no. 2, pp. 563–575, 2000. View at Publisher · View at Google Scholar · View at Scopus
  200. P. Repovic, K. Mi, and E. N. Benveniste, “Oncostatin M enhances the expression of prostaglandin E2 and cyclooxygenase-2 in astrocytes: synergy with interleukin-1β, tumor necrosis factor-α, and bacterial lipopolysaccharide,” Glia, vol. 42, no. 4, pp. 433–446, 2003. View at Publisher · View at Google Scholar · View at Scopus
  201. P. Repovic, C. Y. Fears, C. L. Gladson, and E. N. Benveniste, “Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells,” Oncogene, vol. 22, no. 50, pp. 8117–8124, 2003. View at Publisher · View at Google Scholar · View at Scopus
  202. A. Krona, P. Åman, C. Örndal, and A. Josefsson, “Oncostatin M-induced genes in human astrocytomas,” International Journal of Oncology, vol. 31, no. 6, pp. 1457–1463, 2007. View at Google Scholar · View at Scopus
  203. I. Glezer and S. Rivest, “Oncostatin M is a novel glucocorticoid-dependent neuroinflammatory factor that enhances oligodendrocyte precursor cell activity in demyelinated sites,” Brain, Behavior, and Immunity, vol. 24, no. 5, pp. 695–704, 2010. View at Publisher · View at Google Scholar · View at Scopus
  204. P. Beatus, D. J. Jhaveri, T. L. Walker et al., “Oncostatin M regulates neural precursor activity in the adult brain,” Developmental Neurobiology, vol. 71, no. 7, pp. 619–633, 2011. View at Publisher · View at Google Scholar · View at Scopus
  205. H. J. Kang, J. S. Kang, S. H. Lee et al., “Upregulation of oncostatin M in allergic rhinitis,” Laryngoscope, vol. 115, no. 12, pp. 2213–2216, 2005. View at Publisher · View at Google Scholar · View at Scopus
  206. J. L. Simpson, K. J. Baines, M. J. Boyle, R. J. Scott, and P. G. Gibson, “Oncostatin m (osm) is increased in asthma with incompletely reversible airflow obstruction,” Experimental Lung Research, vol. 35, no. 9, pp. 781–794, 2009. View at Publisher · View at Google Scholar · View at Scopus
  207. A. Mozaffarian, A. W. Brewer, E. S. Trueblood et al., “Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis,” The Journal of Immunology, vol. 181, no. 10, pp. 7243–7253, 2008. View at Google Scholar · View at Scopus
  208. I. G. Luzina, S. P. Atamas, R. Wise et al., “Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients,” Arthritis and Rheumatism, vol. 48, no. 8, pp. 2262–2274, 2003. View at Publisher · View at Google Scholar · View at Scopus
  209. K. J. Baines, J. L. Simpson, and P. G. Gibson, “Innate immune responses are increased in chronic obstructive pulmonary disease,” PLoS ONE, vol. 6, no. 3, Article ID e18426, 2011. View at Publisher · View at Google Scholar · View at Scopus
  210. J. A. Elias, C. G. Lee, T. Zheng, B. Ma, R. J. Homer, and Z. Zhu, “New insights into the pathogenesis of asthma,” The Journal of Clinical Investigation, vol. 111, no. 3, pp. 291–297, 2003. View at Publisher · View at Google Scholar · View at Scopus
  211. S. T. Holgate, “Pathogenesis of asthma,” Clinical and Experimental Allergy, vol. 38, no. 6, pp. 872–897, 2008. View at Publisher · View at Google Scholar · View at Scopus
  212. T. A. Wynn, “Cellular and molecular mechanisms of fibrosis,” Journal of Pathology, vol. 214, no. 2, pp. 199–210, 2008. View at Publisher · View at Google Scholar · View at Scopus
  213. T. A. Wynn, “Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases,” The Journal of Clinical Investigation, vol. 117, no. 3, pp. 524–529, 2007. View at Publisher · View at Google Scholar · View at Scopus
  214. T. A. Wynn and T. R. Ramalingam, “Mechanisms of fibrosis: therapeutic translation for fibrotic disease,” Nature Medicine, vol. 18, pp. 1028–1040, 2012. View at Google Scholar
  215. B. F. DiCosmo, G. P. Geba, D. Picarella et al., “Airway epithelial cell expression of interleukin-6 in transgenic mice. Uncoupling of airway inflammation and bronchial hyperreactivity,” The Journal of Clinical Investigation, vol. 94, no. 5, pp. 2028–2035, 1994. View at Google Scholar · View at Scopus
  216. C. Kuhn III, R. J. Homer, Z. Zhu et al., “Airway hyperresponsiveness and airway obstruction in transgenic mice: morphologic correlates in mice overexpressing interleukin (IL)-11 and IL-6 in the lung,” American Journal of Respiratory Cell and Molecular Biology, vol. 22, no. 3, pp. 289–295, 2000. View at Google Scholar · View at Scopus
  217. W. Tang, G. P. Geba, T. Zheng et al., “Targeted expression of IL-11 in the murine airway causes lymphocytic inflammation, bronchial remodeling, and airways obstruction,” The Journal of Clinical Investigation, vol. 98, no. 12, pp. 2845–2853, 1996. View at Google Scholar · View at Scopus
  218. C. Langdon, C. Kerr, L. Tong, and C. D. Richards, “Oncostatin M regulates eotaxin expression in fibroblasts and eosinophilic inflammation in C57BL/6 mice,” The Journal of Immunology, vol. 170, no. 1, pp. 548–555, 2003. View at Google Scholar · View at Scopus
  219. Z. Xing, T. Braciak, M. Jordana, K. Croitoru, F. L. Graham, and J. Gauldie, “Adenovirus-mediated cytokine gene transfer at tissue sites: overexpression of IL-6 induces lymphocytic hyperplasia in the lung,” The Journal of Immunology, vol. 153, no. 9, pp. 4059–4069, 1994. View at Google Scholar · View at Scopus
  220. Z. Xing, T. Braciak, D. Chong, X. Feng, J.-A. Schroeder, and J. Gauldie, “Adenoviral-mediated gene transfer of interleukin-6 in rat lung enhances antiviral immunoglobulin A and G responses in distinct tissue compartments,” Biochemical and Biophysical Research Communications, vol. 258, no. 2, pp. 332–335, 1999. View at Publisher · View at Google Scholar · View at Scopus
  221. C. D. Richards, C. Kerr, L. Tong, and C. Langdon, “Modulation of extracellular matrix using adenovirus vectors,” Biochemical Society Transactions, vol. 30, no. 2, pp. 107–111, 2002. View at Google Scholar · View at Scopus
  222. T. Lahiri, J. D. Laporte, P. E. Moore, R. A. Panettieri Jr., and S. A. Shore, “Interleukin-6 family cytokines: signaling and effects in human airway smooth muscle cells,” American Journal of Physiology, vol. 280, no. 6, pp. L1225–L1232, 2001. View at Google Scholar · View at Scopus
  223. P. E. Moore, T. L. Church, D. D. Chism, R. A. Panettieri Jr., and S. A. Shore, “IL-13 and IL-4 cause eotaxin release in human airway smooth muscle cells: a role for ERK,” American Journal of Physiology, vol. 282, no. 4, pp. L847–L853, 2002. View at Google Scholar · View at Scopus
  224. D. S. Faffe, L. Flynt, M. Mellema et al., “Oncostatin M causes eotaxin-1 release from airway smooth muscle: synergy with IL-4 and IL-13,” Journal of Allergy and Clinical Immunology, vol. 115, no. 3, pp. 514–520, 2005. View at Publisher · View at Google Scholar · View at Scopus
  225. D. S. Faffe, L. Flynt, M. Mellema et al., “Oncostatin M causes VEGF release from human airway smooth muscle: synergy with IL-1β,” American Journal of Physiology, vol. 288, no. 6, pp. L1040–L1048, 2005. View at Publisher · View at Google Scholar · View at Scopus
  226. C. D. Richards and A. Agro, “Interaction between Oncostatin M, interleukin 1 and prostaglandin E2 in induction of IL-6 expression in human fibroblasts,” Cytokine, vol. 6, no. 1, pp. 40–47, 1994. View at Publisher · View at Google Scholar · View at Scopus
  227. A. K. Scaffidi, S. E. Mutsaers, Y. P. Moodley et al., “Oncostatin M stimulates proliferation, induces collagen production and inhibits apoptosis of human lung fibroblasts,” British Journal of Pharmacology, vol. 136, no. 5, pp. 793–801, 2002. View at Google Scholar · View at Scopus
  228. K. A. O'Hara, M.-A. Kedda, P. J. Thompson, and D. A. Knight, “Oncostatin M: an interleukin-6-like cytokine relevant to airway remodelling and the pathogenesis of asthma,” Clinical and Experimental Allergy, vol. 33, no. 8, pp. 1026–1032, 2003. View at Publisher · View at Google Scholar · View at Scopus
  229. M. Cohen, S. Marchand-Adam, V. Lecon-Malas et al., “HGF synthesis in human lung fibroblasts is regulated by oncostatin M,” American Journal of Physiology, vol. 290, no. 6, pp. L1097–L1103, 2006. View at Publisher · View at Google Scholar · View at Scopus
  230. D. K. Fritz, C. Kerr, F. Botelho, M. Stampfli, and C. D. Richards, “Oncostatin M (OSM) primes IL-13- and IL-4-induced eotaxin responses in fibroblasts: regulation of the type-II IL-4 receptor chains IL-4Rα and IL-13Rα1,” Experimental Cell Research, vol. 315, no. 20, pp. 3486–3499, 2009. View at Publisher · View at Google Scholar · View at Scopus
  231. D. C. Smyth, C. Kerr, Y. Li, D. Tang, and C. D. Richards, “Oncostatin M induction of eotaxin-1 expression requires the convergence of PI3′K and ERK1/2 MAPK signal transduction pathways,” Cellular Signalling, vol. 20, no. 6, pp. 1142–1150, 2008. View at Publisher · View at Google Scholar · View at Scopus
  232. K. Y. Nagahama, S. Togo, O. Holz et al., “Oncostatin M modulates fibroblast function via STAT3,” American Journal of Respiratory Cell and Molecular Biology, vol. 49, no. 4, pp. 582–591, 2013. View at Publisher · View at Google Scholar
  233. C. M. Prele, E. Yao, R. J. O'Donoghue, S. E. Mutsaers, and D. A. Knight, “STAT3: a central mediator of pulmonary fibrosis?” Proceedings of the American Thoracic Society, vol. 9, pp. 177–182, 2012. View at Google Scholar
  234. R. J. O'Donoghue, D. A. Knight, C. D. Richards et al., “Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis,” EMBO Molecular Medicine, vol. 4, pp. 939–951, 2012. View at Google Scholar
  235. P. L. Dudas, G. L. de, L. K. Lundblad, and D. A. Knight, “The role of the epithelium in chronic inflammatory airway disease,” Pulmonary Pharmacology & Therapeutics, vol. 25, pp. 413–414, 2012. View at Google Scholar
  236. J.-M. Sallenave, G. M. Tremblay, J. Gauldie, and C. D. Richards, “Oncostatin M, but not interleukin-6 or leukemia inhibitory factor, stimulates expression of alpha1-proteinase inhibitor in A549 human alveolar epithelial cells,” Journal of Interferon and Cytokine Research, vol. 17, no. 6, pp. 337–346, 1997. View at Google Scholar · View at Scopus
  237. C. McCormick and R. I. Freshney, “Activity of growth factors in the IL-6 group in the differentiation of human lung adenocarcinoma,” British Journal of Cancer, vol. 82, no. 4, pp. 881–890, 2000. View at Google Scholar · View at Scopus
  238. D. A. Knight, N. Asokananthan, D. N. Watkins, N. L. A. Misso, P. J. Thompson, and G. A. Stewart, “Oncostatin M synergises with house dust mite proteases to induce the production of PGE2 from cultured lung epithelial cells,” British Journal of Pharmacology, vol. 131, no. 3, pp. 465–472, 2000. View at Google Scholar · View at Scopus
  239. T. Tomita, A. Yamada, M. Miyakoshi et al., “Oncostatin M regulates secretoglobin 3A1 and 3A2 expression in a bidirectional manner,” American Journal of Respiratory Cell and Molecular Biology, vol. 40, no. 5, pp. 620–630, 2009. View at Publisher · View at Google Scholar · View at Scopus
  240. J. Nightingale, S. Patel, N. Suzuki et al., “Oncostatin M, a cytokine released by activated mononuclear cells, induces epithelial cell-myofibroblast transdifferentiation via Jak/Stat pathway activation,” Journal of the American Society of Nephrology, vol. 15, no. 1, pp. 21–32, 2004. View at Publisher · View at Google Scholar · View at Scopus
  241. R. Sarközi, C. Hauser, S.-J. Noppert et al., “Oncostatin M is a novel inhibitor of TGF-β1-induced matricellular protein expression,” American Journal of Physiology, vol. 301, no. 5, pp. F1014–F1025, 2011. View at Publisher · View at Google Scholar · View at Scopus
  242. W. M. Elbjeirami, L. D. Truong, A. Tawil et al., “Early differential expression of oncostatin M in obstructive nephropathy,” Journal of Interferon and Cytokine Research, vol. 30, no. 7, pp. 513–523, 2010. View at Publisher · View at Google Scholar · View at Scopus
  243. H. Baumann, Y. Wang, C. D. Richards, C. A. Jones, T. A. Black, and K. W. Gross, “Endotoxin-induced renal inflammatory response: oncostatin M as a major mediator of suppressed renin expression,” The Journal of Biological Chemistry, vol. 275, no. 29, pp. 22014–22019, 2000. View at Publisher · View at Google Scholar · View at Scopus
  244. M. R. Duncan, A. Hasan, and B. Berman, “Oncostatin M stimulates collagen and glycosaminoglycan production by cultured normal dermal fibroblasts: insensitivity of sclerodermal and keloidal fibroblasts,” The Journal of Investigative Dermatology, vol. 104, no. 1, pp. 128–133, 1995. View at Google Scholar · View at Scopus
  245. H. Ihn, E. C. LeRoy, and M. Trojanowska, “Oncostatin M stimulates transcription of the human α2(I) collagen gene via the Sp1/Sp3-binding site,” The Journal of Biological Chemistry, vol. 272, no. 39, pp. 24666–24672, 1997. View at Publisher · View at Google Scholar · View at Scopus
  246. H. Ihn and K. Tamaki, “Oncostatin M stimulates the growth of dermal fibroblasts via a mitogen- activated protein kinase-dependent pathway,” The Journal of Immunology, vol. 165, no. 4, pp. 2149–2155, 2000. View at Google Scholar · View at Scopus
  247. C. Hintzen, C. Haan, J. P. Tuckermann, P. C. Heinrich, and H. M. Hermanns, “Oncostatin M-induced and constitutive activation of the JAK2/STAT5/CIS pathway suppresses CCL1, but Not CCL7 and CCL8, chemokine expression,” The Journal of Immunology, vol. 181, no. 10, pp. 7341–7349, 2008. View at Google Scholar · View at Scopus
  248. M. Hasegawa, S. Sato, H. Ihn, and K. Takehara, “Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis,” Rheumatology, vol. 38, no. 7, pp. 612–617, 1999. View at Publisher · View at Google Scholar · View at Scopus
  249. N. Finelt, A. Gazel, S. Gorelick, and M. Blumenberg, “Transcriptional responses of human epidermal keratinocytes to Oncostatin-M,” Cytokine, vol. 31, no. 4, pp. 305–313, 2005. View at Publisher · View at Google Scholar · View at Scopus
  250. K. Boniface, C. Diveu, F. Morel et al., “Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation,” The Journal of Immunology, vol. 178, no. 7, pp. 4615–4622, 2007. View at Google Scholar · View at Scopus
  251. K. Guilloteau, I. Paris, N. Pedretti et al., “Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1α, and TNF-α recapitulates some features of psoriasis,” The Journal of Immunology, vol. 184, no. 9, pp. 5263–5270, 2010. View at Publisher · View at Google Scholar · View at Scopus
  252. J. P. Giot, I. Paris, P. Levillain et al., “Involvement of IL-1 and oncostatin M in acanthosis associated with hypertensive leg ulcer,” The American Journal of Pathology, vol. 182, no. 3, pp. 806–818, 2013. View at Publisher · View at Google Scholar
  253. E. Sonkoly, A. Muller, A. I. Lauerma et al., “IL-31: a new link between T cells and pruritus in atopic skin inflammation,” Journal of Allergy and Clinical Immunology, vol. 117, no. 2, pp. 411–417, 2006. View at Publisher · View at Google Scholar · View at Scopus
  254. W. A. Boisvert, “Modulation of atherogenesis by chemokines,” Trends in Cardiovascular Medicine, vol. 14, no. 4, pp. 161–165, 2004. View at Publisher · View at Google Scholar · View at Scopus
  255. Y. Sheikine and G. K. Hansson, “Chemokines and atherosclerosis,” Annals of Medicine, vol. 36, no. 2, pp. 98–118, 2004. View at Publisher · View at Google Scholar · View at Scopus
  256. I. F. Charo and M. B. Taubman, “Chemokines in the pathogenesis of vascular disease,” Circulation Research, vol. 95, no. 9, pp. 858–866, 2004. View at Publisher · View at Google Scholar · View at Scopus
  257. L. K. Curtiss, N. Kubo, N. K. Schiller, and W. A. Boisvert, “Participation of innate and acquired immunity in atherosclerosis,” Immunologic Research, vol. 21, no. 2-3, pp. 167–176, 2000. View at Google Scholar · View at Scopus
  258. S. A. Huber, P. Sakkinen, D. Conze, N. Hardin, and R. Tracy, “Interleukin-6 exacerbates early atherosclerosis in mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 10, pp. 2364–2367, 1999. View at Google Scholar · View at Scopus
  259. M. Madan, B. Bishayi, M. Hoge, and S. Amar, “Atheroprotective role of interleukin-6 in diet- and/or pathogen-associated atherosclerosis using an ApoE heterozygote murine model,” Atherosclerosis, vol. 197, no. 2, pp. 504–514, 2008. View at Publisher · View at Google Scholar · View at Scopus
  260. J. J. Boyle, “Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture,” Current Vascular Pharmacology, vol. 3, no. 1, pp. 63–68, 2005. View at Publisher · View at Google Scholar · View at Scopus
  261. J. J. Boyle, P. L. Weissberg, and M. R. Bennett, “Tumor necrosis factor-α promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 9, pp. 1553–1558, 2003. View at Publisher · View at Google Scholar · View at Scopus
  262. T. J. Brown, J. M. Rowe, J. Liu, and M. Shoyab, “Regulation of IL-6 expression by oncostatin M,” The Journal of Immunology, vol. 147, no. 7, pp. 2175–2180, 1991. View at Google Scholar · View at Scopus
  263. T. J. Brown, J. Liu, C. Brashem-Stein, and M. Shoyab, “Regulation of granulocyte colony-stimulating factor and granulocyte- macrophage colony-stimulating factor expression by oncostatin M,” Blood, vol. 82, no. 1, pp. 33–37, 1993. View at Google Scholar · View at Scopus
  264. V. Modur, M. J. Feldhaus, A. S. Weyrich et al., “Oncostatin M is a proinflammatory mediator: in vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules,” The Journal of Clinical Investigation, vol. 100, no. 1, pp. 158–168, 1997. View at Google Scholar · View at Scopus
  265. L. Yao, J. Pan, H. Setiadi, K. D. Patel, and R. P. McEver, “Interleukin 4 or oncostatin M induces a prolonged increase in P-selectin mRNA and protein in human endothelial cells,” Journal of Experimental Medicine, vol. 184, no. 1, pp. 81–92, 1996. View at Publisher · View at Google Scholar · View at Scopus
  266. S. M. Kerfoot, E. Raharjo, M. Ho et al., “Exclusive neutrophil recruitment with oncostatin M in a human system,” American Journal of Pathology, vol. 159, no. 4, pp. 1531–1539, 2001. View at Google Scholar · View at Scopus
  267. J. Pourtau, F. Mirshahi, H. Li et al., “Cyclooxygenase-2 activity is necessary for the angiogenic properties of oncostatin M,” FEBS Letters, vol. 459, no. 3, pp. 453–457, 1999. View at Publisher · View at Google Scholar · View at Scopus
  268. K. Rychli, C. Kaun, P. J. Hohensinner et al., “The inflammatory mediator oncostatin M induces angiopoietin 2 expression in endothelial cells in vitro and in vivo,” Journal of Thrombosis and Haemostasis, vol. 8, no. 3, pp. 596–604, 2010. View at Publisher · View at Google Scholar · View at Scopus
  269. M. Vasse, J. Pourtau, V. Trochon et al., “Oncostatin M induces angiogenesis in vitro and in vivo,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 8, pp. 1835–1842, 1999. View at Google Scholar · View at Scopus
  270. R. I. Grove, C. Eberhardt, S. Abid et al., “Oncostatin M is a mitogen for rabbit vascular smooth muscle cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 3, pp. 823–827, 1993. View at Publisher · View at Google Scholar · View at Scopus
  271. C. Bernard, R. Merval, M. Lebret et al., “Oncostatin M induces interleukin-6 and cyclooxygenase-2 expression in human vascular smooth muscle cells: synergy with interleukin-1β,” Circulation Research, vol. 85, no. 12, pp. 1124–1131, 1999. View at Google Scholar · View at Scopus
  272. S. Demyanets, C. Kaun, K. Rychli et al., “Oncostatin M-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves PI3K-, p38 MAPK-, Erk1/2- and STAT1/STAT3-dependent pathways and is attenuated by interferon-γ,” Basic Research in Cardiology, vol. 106, no. 2, pp. 217–231, 2011. View at Publisher · View at Google Scholar · View at Scopus
  273. A. Albasanz-Puig, J. Murray, M. Preusch et al., “Oncostatin M is expressed in atherosclerotic lesions: a role for Oncostatin M in the pathogenesis of atherosclerosis,” Atherosclerosis, vol. 216, no. 2, pp. 292–298, 2011. View at Publisher · View at Google Scholar · View at Scopus
  274. K. Macfelda, T. W. Weiss, C. Kaun et al., “Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1α, tumor necrosis factor-α, transforming growth factor-β and oncostatin M in human cardiac myocytes,” Journal of Molecular and Cellular Cardiology, vol. 34, no. 12, pp. 1681–1691, 2002. View at Publisher · View at Google Scholar · View at Scopus
  275. T. W. Weiss, W. S. Speidl, C. Kaun et al., “Glycoprotein 130 ligand oncostatin-M induces expression of vascular endothelial growth factor in human adult cardiac myocytes,” Cardiovascular Research, vol. 59, no. 3, pp. 628–638, 2003. View at Publisher · View at Google Scholar · View at Scopus
  276. T. W. Weiss, H. Kvakan, C. Kaun et al., “The gp130 ligand oncostatin M regulates tissue inhibitor of metalloproteinases-1 through ERK1/2 and p38 in human adult cardiac myocytes and in human adult cardiac fibroblasts: a possible role for the gp130/gp130 ligand system in the modulation of extracellular matrix degradation in the human heart,” Journal of Molecular and Cellular Cardiology, vol. 39, no. 3, pp. 545–551, 2005. View at Publisher · View at Google Scholar · View at Scopus
  277. P. J. Hohensinner, C. Kaun, K. Rychli et al., “The inflammatory mediator oncostatin M induces stromal derived factor-1 in human adult cardiac cells,” FASEB Journal, vol. 23, no. 3, pp. 774–782, 2009. View at Publisher · View at Google Scholar · View at Scopus
  278. T. Kubin, J. Pöling, S. Kostin et al., “Oncostatin M is a major mediator of cardiomyocyte dedifferentiation and remodeling,” Cell Stem Cell, vol. 9, no. 5, pp. 420–432, 2011. View at Publisher · View at Google Scholar · View at Scopus